|
 |
European Pharmaceutical Contractor
|
With the European Union almost doubling its member size to 25 on 1st May 2004, there remains much industry speculation regarding how much of a driver for drug sales this will be. The greatest area of uncertainty is pricing and the inevitable complexity of European reimbursement policies, especially in the light of government encouraged cost-containment of health care expenditure. The pharmaceutical industry is under pressure to ensure drug prices remain buoyant and, most importantly, persuade emergent health care payers in post-accession Europe to utilise their drugs.
The accession of 10 new members - the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, Slovenia, Malta and Cyprus - to the EU in May marks largely uncharted waters for the European-focused pharmaceutical industry (pharma). This is primarily due to the deficiencies/ diversities of current diagnostic and treatment options in the newer member states. Notably, the expansion of the market to include over 450 million people increases the promise of ever-expanding revenue streams, but equally raises the question of whether newer member states have the health care infrastructure to afford innovative drugs.
More importantly, doubts remain over the issue of pan-European pricing being affected by the health care systems of accession countries - could branded pharmaceuticals stand up to the threat of cheaper alternatives stemming from parallel trade or generics? Consequently, within the context of price-regulated Europe, the question remains as to how pharmaceutical companies could ensure that pricing and reimbursement policies after 1st May 2004 do not diminish a product's launch success in the enlarged EU.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
